Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.

• DOI: 10.1200/jco.1996.14.1.142
• Publication Date: 2017-02-24T09:47:10Z
• Authors: M J Millward; J F Bishop; M Friedlander; J A Levi; D Goldstein; I N Olver; J G Smith; G C Toner; D Rischin; D R Bell
• Keywords: Premedication

To determine the antitumor activity and toxicity of paclitaxel administered as a 3-hour infusion in patients with advanced non-small-cell lung cancer (NSCLC).Fifty-one measurable or assessable NSCLC performance status 0 to 2 who had not received prior chemotherapy were treated 175 mg/m2 over 3 hours premedication. Cycles repeated every weeks for maximum nine cycles. Most radiotherapy (57%), extrathoracic metastatic disease (65%), (75%). Twenty-two percent previously untreated stage III disease.The objective response rate was five 51 (10%; 95% confidence interval, 3% 21%). No subgroup higher could be identified. There no complete responses (CRs) all lasted less than 5 months. Treatment well tolerated brief World Health Organization (WHO) grade IV neutropenia only 16% patients. Grade III/IV myalgia/athralgia occurred 22% significant hypersensitivity reactions occurred.The this dose schedule appears inferior that reported published phase II trials used doses infused 24 hours, although intervals overlap. Determining optimal using requires further investigation, these results should caution against shorter infusions outside appropriate clinical trials.